. 2022 May 13;14(10):2412. doi: 10.3390/cancers14102412

Table 1.

Incidence rates of GBM for both genders.

Reference	Year Range	Country	Population Size (n)	Incidence/ 100,000/Year Male	Incidence/ 100,000/Year Female	Incidence/ 100,000/Year Male and Female	Age
Brodbelt et al., 2015 [29]	2007–2011	England	10,743	5.87 (5.73–6.02) ^b	3.54 (3.44–3.65) ^b	4.64 (4.56–4.73) ^b	all
Chakrabarti et al., 2005 [30]	1974–1999	USA	3832	2.68 (95% CI 2.56–2.80) ^a	1.67 (95% CI 1.59–1.75) ^a	2.11 (95% CI 2.0–2.17) ^a	≥20
Dho et al., 2017 [86]	2013	Republic of Korea	19	0.12 ^j	0.17 ^j	0.87 ^j	0–19
Dho et al., 2017 [86]	2013	Republic of Korea	629	0.99 ^j	0.78 ^j	0.87 ^j	all
Dobec-Meić et al., 2006 [87]	1996–2004	Croatia	63	5.1 ^g	4.6 ^g	4.8, (95% CI 3.7–6.2) ^g	≥18
Dobes et al., 2011 [88]	2000–2008	Australia	2197	-	-	3.96 (3.37–4.52) ^a	all/not specified
Fabbro-Peray et al., 2019 [6]	2008–2015	France	2053	-	-	3.3 ^f	all
Fleury et al., 1997 [89]	1983–1990	France	764	3.09 ^b	1.94 ^b	2.38 ^b	all
Fuentes-Raspall et al., 2011 [90]	1994–2005	Spain	134	-	-	1.59 ^d	all
Fuentes-Raspall et al., 2017 [91]	1994–2013	Spain	463	5.05 (4.45; 5.72) ^e	3.44 (2.97; 3.96) ^e	4.17 (95% CI 3.80; 4.57) ^e	all
Gittleman et al., 2018 [92]	2000–2014	USA	150,399			4.40 (4.38–4.42 95% CI) ^a	>20
Gousias et al., 2009 [93]	2005–2007	Northwest Greece	36	4.12 ^k	3.26 ^k	3.69 ^k	all
Hansen et al., 2018 [31]	2009–2014	Denmark	1364	6.3 ^h	3.9 ^h	-	19–89
Ho et al., 2014 [94]	1989–2010	Netherlands	9504	3.2 ^b	1.9 ^b	2.5 ^b	≥18
Jazayeri et al., 2013 [95]	2000–2009	Iran	3101	-	-	0.76 (0.70–0.83) ^g	all
Jung et al., 2013 [96]	2010	Republic of Korea	523	0.89 ^j	0.95 ^j	0.77 ^j	all
Li et al., 2018 [32]	1973–2014	USA	28,835	-	-	4.1 ^l	>20
Larjavaara et al., 2007 [97]	2000–2002	Finland	154	-	-	2 ^d	20–69
Natukka et al., 2019 [98]	1990–2006	Finland	2284	-	-	3.8 (95% CI 3.7–4.0) ^e	all
Natukka et al., 2019 [98]	2007–2016	Finland	1776	-	-	3.5 ^e	all
Ohgaki et al., 2004 [99]	1980–1994	Switzerland	715	3.32 (CI, 2.69–4.09) ^d	2.24 (CI, 1.56–3.22) ^d	-	all
Ostrom et al., 2013 [100]	2006–2010	USA	50,872	3.97 ^a	2.53 ^a	3.19 ^a	all
Ostrom et al., 2017 [101]	2010–2014	USA	56,421	3.99 (3.95–4.03 95% CI) ^a	2.52 (2.49–2.56 95% CI) ^a	3.20 (3.17–3.23 95% CI) ^a	all
Ostrom et al., 2020 [14]	2013–2017	USA	60,056	4.03 (95% CI 3.98–4.07) ^a	2.54 (95% CI 2.50–2.57) ^a	3.23 (CI (95% 3.20–3.25) ^a	all
Schoenberg et al., 1976 [102]	1935–1964	Connecticut	1167	2.07 ⁱ	1.51 ⁱ	-	all
Walker et al., 2019 [103]	2009–2013	Canada	5830	4.91 (95% CI 4.75–5.08) ^c	3.24 (3.11; 3.37) ^c	4.06 (3.95; 4.16) ^c	all
Wanner et al., 2020 [104]	2009–2012	Georgia	72	0.59 (0.42; 0.82) ^a	0.42 (0.29; 0.59) ^a	-	all

^a Age-adjusted using the 2000 US standard population, ^b European age-adjusted incidence, ^c Adjusted to the 2011 Canadian census age distribution, ^d Age-standardized to the world’s standard population, ^e Adjusted to the 2013 European standard population, ^f Crude rate, ^g No information, ^h Age adjustment not specified, ⁱ All age adjustments used the direct method and the population of the United States in 1950 as the standard, ^j Adjusted to Segi’s world standard population, ^k Adjusted to the Greek population, ^l Annual age-standardized incidence rates (ASRs; per 100,000 population), n—number of subgroup members.